Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

Condition(s) studied

Investigational drug(s) / intervention(s)

larotrectinib(Vitrakvi, BAY2757556): In the study, patients treated under local standard of care clinical practice; all decisions in terms of diagnostic procedures, treatments, management of the disease, and resource utilization are fully dependent on mutual agreement between the patient and the attending physician, without interference by the study initiator or study protocol

Study summary

In this observational study researcher want to learn more about the effectiveness of drug VITRAKVI (generic name: larotrectinib) and how well the drug is tolerated during routine use in patients with TRK fusion cancer which is locally advanced or spread from the place where it started to other places in the body. TRK fusion cancer is a term used to describe a variety of common and rare cancers that are caused by a change to the NTRK (Neurotrophic Tyrosine Kinase) gene called a fusion. During this fusion, an NTRK gene joins together, or fuses, with a different gene. This joining results in the activation of certain proteins (TRK fusion proteins), which can cause cancer cells to multiply and form a tumor. VITRAKVI is an approved drug that blocks the action of the NTRK gene fusion. This study will enroll adult and paediatric patients suffering from a solid tumor with NTRK gene fusion for whom the decision to treat their disease with VITRAKVI has been made by their treating physicians. During the study, patients' medical information such as treatment information with VITRAKVI, other medication or treatments, changes in disease status and other health signs and symptoms will be collected within the normal medical care by the treating doctor. Participants will be observed over a period from 24 to 60 months.

Eligibility

Primary outcome measure(s)

• Number of participants with treatment-emergent adverse events (TEAEs) — Up to 30 days after last dose
• Severity of TEAEs — Up to 30 days after last dose
• Seriousness of TEAEs — Up to 30 days after last dose
• Reasonable causal relationship between larotrectinib and an AE — Up to 30 days after last dose
• Causality of TEAEs — Up to 30 days after last dose
• Action taken related to larotrectinib treatment — Up to 30 days after last dose

Trial sites (76)

+ 36 more sites — see the full list on the official registry below.

More Bayer trials in the UK